Rani Therapeutics entered an agreement with Chugai to pair Rani’s oral biologic delivery capsule with a Chugai experimental rare‑disease antibody in a deal valued up to $1.08 billion, signalling continuing investor and partner interest in non‑injectable biologic platforms. The collaboration covers development rights and milestones and was announced with financial terms and program scope. Separately, Orsini — a rare‑disease pharmacy solutions company — partnered with Paynela to broaden patient affordability programs, aiming to streamline financial assistance and copay support for specialty drug beneficiaries. The agreement focuses on integrating technology to reduce patient cost barriers. The two deals highlight industry emphasis on alternative delivery formats to broaden patient uptake and on payer/patient support tools to manage access for high‑cost rare disease therapies.